• Azərbaycan
  • Bosanski
  • Dansk
  • Deutsch
  • Eesti
  • English
  • Español
  • Français
  • Hrvatski
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Nederlands (België)
  • Norsk
  • Polski
  • Português
  • Română
  • Shqip
  • Slovenčina
  • Slovenščina
  • Suomi
  • Svenska
  • Türkçe
  • Čeština
  • Ελληνικά
  • Български
  • Македонски
  • Русский
  • Српски
  • Українська
  • עברית
  • العربية

Welcome to the CF Europe Access2Meds survey!

What is this survey for?

CF Europe and the Cystic Fibrosis Trust are sending out a survey to help us learn how people across Europe get access to cystic fibrosis medicines. This survey will be distributed to 38 CF Europe member countries to get an accurate picture of access to medications in different countries and have the voices of the community heard.  

Who should complete this survey?

This survey is for people with cystic fibrosis, the family members/caregivers of people with CF, and CF clinicians. The survey has six sections and will take 10-15 minutes to complete. For people with CF under the age of 16 years, we recommend a parent/caregiver should complete this survey on their behalf.

How will the results be used?

By completing this survey, your answers will help us to understand the experiences and perceptions of access to different CF medications across countries, and also how the coronavirus (COVID-19) pandemic has affected your access to medications.

Your answers will be anonymous, and we won’t ask for any information that could identify you. The information you provide will be collected by the Cystic Fibrosis Trust on behalf of CF Europe and will be combined with information from people across Europe. Upon completion of the analysis the team hopes to publish a report of any findings in an academic journal. The results may help to influence future policy action across Europe and identify areas for further work or research.

We are very grateful to you for taking the time to complete this survey. Your answers will help us to understand access to medicines in your country and help improve cystic fibrosis care for all of Europe.
0 of 45 answered